AGIO – agios pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
3/5
02:48 pm
agio
Low
Agios Pharmaceuticals (AGIO) had its price target raised by Citigroup Inc. from $38.00 to $46.00. They now have a "buy" rating on the stock.
3/4
09:21 am
agio
Low
How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets [Yahoo! Finance]
3/4
09:00 am
agio
Medium
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - AGIO
3/3
09:00 am
agio
Medium
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO
3/2
09:22 pm
agio
Low
Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction [Yahoo! Finance]
2/12/2026
06:30 am
AGIO
1.0%
MISS
10/30/2025
06:30 am
AGIO
2.9%
BEAT
7/31/2025
06:30 am
AGIO
-0.5%
MISS
5/1/2025
06:30 am
AGIO
1.1%
BEAT
3/5
02:35 pm
Maintains
Buy
Buy
Citigroup
Low
-1.1%
3/5
02:35 pm
Maintains
Buy
Buy
Citigroup
Low
-1.1%
1/6
01:10 pm
Maintains
Neutral
Neutral
JP Morgan
Low
0.5%
12/26
09:59 am
Maintains
Outperform
Outperform
Leerink Partners
Low
0.9%
12/26
09:02 am
Reiterates
Buy
Buy
Citigroup Inc.
Medium
-3.7%
3/5
04:28 pm
agio
Low
Form 144 AGIOS PHARMACEUTICALS, Filed by: Viswanadhan Krishnan
3/5
04:08 pm
agio
Low
Form 4 AGIOS PHARMACEUTICALS, For: Mar 03 Filed by: Washburn Theodore James Jr.
3/3
04:21 pm
agio
Low
Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Goff Brian
3/3
04:21 pm
agio
Low
Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Burns James William
3/3
04:21 pm
agio
Low
Form 4 AGIOS PHARMACEUTICALS, For: Mar 01 Filed by: Gheuens Sarah
Show more
Top News Gainers
1/13 Form 8-K AGIOS PHARMACEUTICALS, For: Jan 13 8.7%
11/5 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its price target lowered by analysts at Citigroup Inc from $80.00 to $64.00. They now have a "buy" rating on the stock. 7.9%
9/10 Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO 6.2%
10/2 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.6%
12/9 Form 8-K AGIOS PHARMACEUTICALS, For: Dec 08 5.4%
6/14 Form 4 AGIOS PHARMACEUTICALS For: Jun 12 Filed by: MARAGANORE JOHN 5.4%
2/13 Q4/2019 12/31/2019 EPS -1.600 ZacksConsensus -1.780 ActVsEst 0.180 - Beat 5.3%
7/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 5.1%
5/15 Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients 5.0%
4/16 Form DEF 14A AGIOS PHARMACEUTICALS, For: May 28 5.0%
Top News Decliners
5/1 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $72.00 price target on the stock. -13.0%
8/1 Form 10-Q AGIOS PHARMACEUTICALS, For: Jun 30 -11.2%
12/9 Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML) -8.8%
5/16 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "buy" rating re-affirmed by analysts at Cowen Inc. -7.9%
4/30 Agios Pharmaceuticals Inc (NASDAQ: AGIO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.6%
1/13 TIO Bioventures Launches Treadwell Therapeutics, Seeded With $27m to Develop First-in-Class Oral Medicines Against Novel Targets -6.2%
10/28 Form 8-K AGIOS PHARMACEUTICALS, For: Oct 27 -6.2%
9/30 Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients -6.2%
2/24 Form 4 AGIOS PHARMACEUTICALS, For: Feb 20 Filed by: Alenson Carman -6.0%
2/14 Agios Pharmaceuticals Inc (NASDAQ: AGIO) had its "hold" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. -5.1%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3